Table 2 |
|||
|
Effects of co-immunization with altered peptide ligands on the development of arthritis |
|||
|
Co-immunization |
Incidence |
Day of onset |
Maximum severity |
|
|
|||
|
None |
8/8 |
10 ± 0.0 |
10.9 ± 1.4 |
|
APL 6 |
8/8 |
10 ± 0.0 |
7.5 ± 2.0* |
|
APL 7 |
6/8 |
10 ± 0.0 |
7.8 ± 1.7* |
|
APL 12 |
7/8 |
10.3 ± 0.8 |
5.0 ± 1.2** |
|
APL 13 |
3/8† |
10 ± 0.0 |
4.0 ± 0.0** |
|
|
|||
|
Mice were co-immunized with 10 μg glucose-6-phosphate isomerase hGPI325--339and 50 μg indicated antigen. Data presented as incidence or mean ± standard deviation. †P < 0.05 (Fisher's exact test). *P < 0.005, **P < 0.001 (Mann--Whitney U test). |
|||
|
Iwanami et al. Arthritis Research & Therapy 2009 11:R167 doi:10.1186/ar2854 |
|||
